Hyperhomocysteinemia in Alzheimer's Disease

Alzheimer Disease Clinical Trial

— Hcy-MA  

Official title:

Hyperhomocysteinemia in Alzheimer's Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05793372
• Other study ID #: 2023PI049
• Status: Not yet recruiting
• Start date: June 2023
• Est. completion date: March 1, 2026

Study information

• Verified date: May 2023
• Source: Central Hospital, Nancy, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Alzheimer's disease (AD) is the most common neurodegenerative disease. Age is its main risk factor. AD is a multifactorial disease, combining genetic and environmental risk factors. Autosomal dominant mutations have been identified (PSEN1, PSEN2, APP), leading to earlier and more severe forms of the disease. Other genetic risk factors have been identified, such as the ε4 allele of the APOE gene. . The environment also plays a major role, with the identification of several risk factors such as air pollution or nutritional deficiencies. AD patients frequently present hyperhomocysteinemia, a consequence of a dysfunction of monocarbon metabolism. Homocysteine is an amino acid involved in the metabolism of methionine and cysteine. High concentrations of homocysteine can be deleterious to the central nervous system. Most prospective studies have shown that elevated homocysteine is a predictor of undefined cognitive impairment or AD. Other studies have focused on clinical data and, in particular, on cognitive function. For example, a meta-analysis found an inverse correlation between MMSE score and homocysteine level. Thus, our study seeks to evaluate the impact of hyperhomocysteinemia on the severity and early onset of AD, while knowing the presence or absence of genetic risk factors associated with AD.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 43
• Est. completion date: March 1, 2026
• Est. primary completion date: June 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Clinical diagnosis of Alzheimer's disease
• Positive CSF biomarkers
• age of onset < 75 years
• already benefited from a previous research of Alzheimer's disease genetic features (PSEN1, PSEN2, APP, APOE)
• already benefited from a previous research of homocysteine cycle (monocarbon metabolism) by complete exome/clinical exome or panel

Exclusion Criteria:

• patient refusal

Related Conditions & MeSH terms

• Alzheimer Disease
• Hyperhomocysteinemia

Intervention

Other:
• Retrospective study of clinical features
Retrospective study of clinical features

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation between homocysteine levels and the severity/early onset of Alzheimer's disease	Mesure of homocysteine levels Mesure of MiniMental State Evaluation (MMSE), age of symptoms onset	baseline
Secondary	Evaluation of the frequency of hyperhomocysteinemia in a homogeneous population of patients with Alzheimer's disease.	measurement of homocysteine levels in our cohort (µmol/L)	baseline
Secondary	Evaluation of the genetic characteristics of Alzheimer's disease Evaluation of the genetic characteristics of homocysteine monocarbon metabolism.	search for an autosomal dominant mutation (APP, PSEN1 or PSEN2) or a risk factor mutation for Alzheimer's disease (TREM2, SORL1, ABCA7) and APOE status search for a mutation in the genes of monocarbon metabolism	baseline
Secondary	Evaluation of the frequency of vitamin B deficiencies in a homogeneous population of patients with Alzheimer's disease.	measurement of B1,B6,B9 and B12 levels in our cohort (nmol/L)	baseline